Wegovy: sales of weight loss injection more than double - The company said more than 45 million people were now ‘benefitting ...

Is compounded semaglutide effective for weight loss? Here’s the short version: Compounded semaglutide isn’t approved by the ...

Ozempic and Wegovy maker Novo Nordisk quieted Wall Street's concerns with its fourth-quarter results and 2025 outlook.

In fact, Novo Nordisk recently reported positive results for one of its anti-obesity candidates that puts its current ...

As the ‘miracle’ drugs sweep the globe, pubs, bars and drinks manufacturers are scrambling to cope with an unexpected side ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

While popular drugs like Ozempic and Wegovy are only available as injections, drugmaker Novo Nordisk is working on a more ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market.

Federal officials are targeting the blockbuster drugs as part of their ongoing initiative to lower drug costs.

And based on the data so far, amycretin looks even more impressive than Wegovy and Eli Lilly's Zepbound, the two top-selling weight loss drugs. In a 72-week study, Zepbound's mean weight loss was ...